Vascular cognitive impairment (VCI) in elderly is a medical crisis in the United States. VCI is closely associated with hypertension. 67 millions of adults in the United States (33.3% of the population) have hypertension and over 40% of hypertensive patients develop VCI. The Medicare costs for the treatment of hypertension exceeds $47 billion/year and 159 billion/year for dementia. Aged people, especially those with hypertension that is associated with a higher incidence of developing vascular cognitive impairments (VCI) commonly have impaired myogenic response and autoregulation of cerebral blood flow (CBF). However, the mechanism of how these cerebral vascular impairments contribute to the development of VCI is still obscure, part of the reason has been the lack of genetic animal models exhibiting an impaired myogenic response. We first discovered that FHH rats have impaired myogenic response of middle cerebral artery (MCA) and fail to autoregulate in the cerebral circulation, and this impairment is restored by substitution of 2.4 Mbp of chromosome 1 of Brown Norway (BN) rats containing 15 genes including Add3. In the preliminary studies, we found that the expression of Add3 is reduced in FHH relative to FHH.1BN rats and the rescued vascular reactivity of MCA in FHH.1BN rats was back to be impaired after knocking down of Add3 using DsiRNA. We also have preliminary results in the whole animal level to support this view using our newly generated Add3 transgenic and knockout (KO) rat models. As expected, KO of Add3 impairs, and knockin of wildtype (WT) Add3 enhances the myogenic response in freshly isolated MCA in vitro and autoregulation of CBF in vivo. Moreover, we observed vascular remodeling, blood-brain barrier (BBB) leakage, neurodegeneration, learning and memory cognitive impairments those are all characters' of VCI after induction of hypertension in FHH rats. Thus, we hypothesize that Add3 plays an important role in the regulation of impaired myogenic response and autoregulation of CBF, and contributes to the development of age and hypertension related VCI in FHH rats. In this proposal, we will use our newly created Add3 transgenic FHH rats (FHH.Add3TG) vs. FHH rats to examine the myogenic response and autoregulation of CBF, as well as the development of VCI as they age and after the induction of hypertension. These studies should provide novel insights into the role of Add3 in the regulation of the myogenic response and its contribution to age-related small vessel disease, especially in hypertensive individuals, and supply the scientific community with the first genetic animal model in which the myogenic response is impaired to study mechanisms involved in VCI as age. The results will be critical for the development of new treatments to postpone the onset of age and hypertension related vascular diseases.

Public Health Relevance

Impaired autoregulation of cerebral blood flow with increased transmission pressure to the cerebral microcirculation has long been thought to promote the age-related vascular cognitive impairments in hypertensive patients but mechanism involved is unknown partly due to the lack of appropriate genetic animal models. This proposal will characterize our newly developed rat models to investigate the role of Add3 in mediating the impaired myogenic response and autoregulation that contributes to age and hypertension related vascular dementia in FHH rats based on our recent discovery that transfer of a small segment of chromosome 1 containing just 15 genes including Add3 from a normal rat named BN onto the FHH rat corrects the impairment of cerebral vascular function. In this proposal, we will test the hypothesis that Add3 gene is responsible for accelerated decline in cognitive ability with aging and hypertension in FHH rats and provide the scientific community with the first genetic animal model in which the myogenic response is impaired to study mechanisms involved in end organ damage and present information critical to the development of new treatments to prevent age and hypertension related vascular dementia.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AG050049-01A1
Application #
9035493
Study Section
Aging Systems and Geriatrics Study Section (ASG)
Program Officer
Wagster, Molly V
Project Start
2016-01-01
Project End
2017-11-30
Budget Start
2016-01-01
Budget End
2016-11-30
Support Year
1
Fiscal Year
2016
Total Cost
$190,625
Indirect Cost
$65,625
Name
University of Mississippi Medical Center
Department
Pharmacology
Type
Schools of Medicine
DUNS #
928824473
City
Jackson
State
MS
Country
United States
Zip Code
39216
Zhang, Chao; Booz, George W; Yu, Qing et al. (2018) Conflicting roles of 20-HETE in hypertension and renal end organ damage. Eur J Pharmacol 833:190-200
Li, Long-Yang; Wu, Xiao-Lin; Roman, Richard J et al. (2018) Diffusion-weighted 7.0T Magnetic Resonance Imaging in Assessment of Intervertebral Disc Degeneration in Rats. Chin Med J (Engl) 131:63-68
Muroya, Yoshikazu; He, Xiaochen; Fan, Letao et al. (2018) Enhanced Renal Ischemia-Reperfusion Injury in Aging and Diabetes. Am J Physiol Renal Physiol :
Shekhar, Shashank; Cunningham, Mark W; Pabbidi, Mallikarjuna R et al. (2018) Targeting vascular inflammation in ischemic stroke: Recent developments on novel immunomodulatory approaches. Eur J Pharmacol 833:531-544
Roman, Richard J; Fan, Fan (2018) 20-HETE: Hypertension and Beyond. Hypertension 72:12-18
Roman, Richard J; Fan, Fan (2018) Genetic Susceptibility to Hypertension-Induced Renal Injury. Hypertension 71:559-560
Lv, Wenshan; Booz, George W; Fan, Fan et al. (2018) Oxidative Stress and Renal Fibrosis: Recent Insights for the Development of Novel Therapeutic Strategies. Front Physiol 9:105
Lv, Wenshan; Fan, Fan; Wang, Yangang et al. (2018) Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD. Physiol Genomics 50:20-34
Shekhar, Shashank; Liu, Ruen; Travis, Olivia K et al. (2017) Cerebral Autoregulation in Hypertension and Ischemic Stroke: A Mini Review. J Pharm Sci Exp Pharmacol 2017:21-27
Fan, Fan; Roman, Richard J (2017) GPR75 Identified as the First 20-HETE Receptor: A Chemokine Receptor Adopted by a New Family. Circ Res 120:1696-1698

Showing the most recent 10 out of 19 publications